Skip to main content

Table 1 Baseline Characteristics and Demographics.

From: The rainbow cohort: 96 week follow-up of saquinavir-containing regimens in previously antiretroviral therapy (ART)-naïve and pre-treated but protease inhibitor (PI)- naïve hiv-infected patients

  ART-naïve patients (n = 175) Pretreated, but PI-naïve patients (n = 109)
Male (n) 86% (n = 150) 79% (n = 86)
Age in years, Median (IQR) 39 (33; 46) 41 (37; 50)
Height in cm, Median, (IQR) 176 (172; 183) 178 (170; 182)
Weight in kg, Median (IQR) 72 (65; 79) 72 (65; 80)
Hepatitis B coinfection 5% (n = 9) 2% (n = 2)
Hepatitis C coinfection 12% (n = 21) 10% (n = 11)
Infection mode   
MSM 61% 59%
Heterosexual 19% 17%
IVDU 6% 6%
Not specified 14% 18%
Race   
Caucasian 85% 78%
African 8% 11%
Asian 3% 5%
Not specified 4% 6%
CDC stage   
A 38% 29%
B 33% 51%
C 27% 17%
Not specified 2% 3%
Time since first diagnosis in years, Median (IQR) 1 (0; 4) 9 (5; 13)
Time since first ART in months, Median (IQR) - 79 (37; 104)
Number of previous regimen, Median (IQR) - 3 (2; 4)
Treatment interruption before start of new regimen - 28% (n = 30)
Duration of treatment interruption in months, Median (IQR) - 24 (6; 40)
HIV RNA (copies/mL), Median (IQR) 117,000 3,433
  (36,548; 336,000) (92; 34,384)
CD4-count (cells/mm 3 ) Median (IQR) 196 (82; 284) 319 (204; 478)
  1. IQR: Inter quartile range; MSM: Men who have sex with men; CDC: Center for Disease Control; ART: Antiretroviral therapy; NRTIs: nucleoside reverse transcription inhibitors; PI: Protease inhibitor; IVDU: Intravenous Drug Use